Page 173 - 南京医科大学学报自然科学版
P. 173
第41卷第7期 林 欢,冯旰珠. 冠状病毒Spike蛋白及其针对性治疗研究进展[J].
2021年7月 南京医科大学学报(自然科学版),2021,41(07):1095-1103 ·1103 ·
stably expressed in CHO cells[J]. BiochemBiophys Res tory syndrome coronavirus[J]. Viral Immunol,2005,18
Commun,2009,384(4):486-490 (2):327-332
[53] DU L,ZHAO G,CHAN C C,et al. A 219⁃mer CHO⁃ex⁃ [63] KIM M H,KIM H J,CHANG J. Superior immune respons⁃
pressing receptor⁃binding domain of SARS⁃CoV S protein es induced by intranasal immunization with recombinant
induces potent immune responses and protective immunity adenovirus ⁃ based vaccine expressing full ⁃ length Spike
[J]. Viral Immunol,2010,23(2):211-219 protein of Middle East respiratory syndrome coronavirus
[54] WANG Q,WONG G,LU G,et al. MERS⁃CoV spike pro⁃ [J]. PLoS One,2019,14(7):e0220196
tein:Targets for vaccines and therapeutics[J]. Antiviral [64] BHATTACHARYA M,SHARMA A R,PATRA P,et
Res,2016,133:165-177 al. Development of epitope⁃based peptide vaccine against
[55] GAO Q,BAO L,MAO H,et al. Development of an inacti⁃ novel coronavirus 2019(SARS⁃COV⁃2):immunoinformat⁃
vated vaccine candidate for SARS⁃CoV⁃ 2[J]. Science, ics approach[J]. J Med Virol,2020,92(6):618-631
2020,369(6499):77-81 [65] TIAN J H,PATEL N,HAUPT R,et al. SARS ⁃ CoV ⁃ 2
[56] ZHANG Y,ZENG G,PAN H,et al. Immunogenicity and spike glycoprotein vaccine candidate NVX⁃CoV2373 im⁃
safety of a SARS⁃CoV⁃ 2 inactivated vaccine in healthy munogenicity in baboons and protection in mice[J]. Nat
adults aged 18⁃59 years:report of the randomized,double⁃ Commun,2021,12(1):372
blind,andplacebo⁃controlled phase 2 clinical trial[J/OL]. [66] KEECH C,ALBERT G,CHO I,et al. Phase 1⁃2 trial of a
medRxiv,doi:10.1101/2020.07.30.20161216 SARS⁃CoV⁃2 recombinant spike protein nanoparticle vac⁃
[57] WANG H,ZHANG Y,HUANG B,et al. Development of cine[J]. N Engl J Med,2020,383(24):2320-2332
an inactivated vaccine candidate,BBIBP⁃CorV,with po⁃ [67] PARDI N,HOGAN M J,PORTER F W,et al. mRNA vac⁃
tent protection against SARS⁃CoV⁃2[J]. Cell,2020,182 cines⁃a new era in vaccinology[J]. Nat Rev drug discov,
(3):713-721.e9 2018,17(4):261-279
[58] XIA S,ZHANG Y,WANG Y,et al. Safety and immunoge⁃ [68] ZENG C,ZHANG C,WALKER P G,et al. Formulation
nicity of an inactivated SARS ⁃ CoV ⁃ 2 vaccine,BBIBP ⁃ and delivery technologies for mRNA vaccines[J]. Curr
CorV:a randomised,double ⁃ blind,placebo ⁃ controlled, top Microbiol Immunol,2020,doi:10.1007/82_2020_217
phase 1/2 trial[J]. Lancet Infect Dis,2021,21(1):39-51 [69] CORBETT K S,EDWARDS D K,LEIST S R,et al. SARS⁃
[59] XIA S,DUAN K,ZHANG Y,et al. Effect of an inactivat⁃ CoV⁃2 mRNA vaccine design enabled by prototype patho⁃
ed vaccine against SARS⁃CoV⁃2 on safety and immunoge⁃ gen preparedness[J]. Nature,2020,586(7830):567-571
nicity outcomes:interim analysis of 2 randomized clinical [70] JACKSON L A,ANDERSON E J,ROUPHAEL N G,et al.
trials[J]. JAMA,2020,324(10):951-960 An mRNA vaccine against SARS⁃CoV⁃2 ⁃ preliminary re⁃
[60] WANG F,KREAM R M,STEFANO G B. An evidence port[J]. N Engl J Med,2020,383(20):1920-1931
based perspective on mRNA⁃SARS⁃CoV⁃2 vaccine devel⁃ [71] KIM E,ERDOS G,HUANG S,et al. Microneedle array de⁃
opment[J]. Med Sci Monit,2020,26:e924700 livered recombinant coronavirus vaccines:immunogenici⁃
[61] HODGSON S H,MANSATTA K,MALLETT G,et al. ty and rapid translational development[J]. EBioMedi⁃
What defines an efficacious COVID⁃19 vaccine? A review cine,2020,55:102743
of the challenges assessing the clinical efficacy of vac⁃ [72] 周廉政,张明顺,吉宁飞,等. 新型冠状病毒肺炎潜在治
cines against SARS⁃CoV⁃2[J]. Lancet Infect Dis,2021, 疗药物研究进展[J]. 南京医科大学学报(自然科学版),
21(2):e26-e35 2020,40(3):315-321
[62] HE Y,JIANG S. Vaccine design for severe acute respira⁃ [收稿日期] 2020-10-23